TY - JOUR
T1 - Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma
AU - Jain, Lokesh
AU - Gardner, Erin R.
AU - Venitz, Jürgen
AU - Dahut, William
AU - Figg, William D.
N1 - Funding Information:
This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.
Funding Information:
This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400 (ER Gardner). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
PY - 2008/1/22
Y1 - 2008/1/22
N2 - A rapid and sensitive liquid chromatography/tandem mass spectrometric (LC/MS/MS) assay was developed for the quantitative determination of sorafenib in human plasma. Sample pretreatment involved simple protein precipitation by the addition of 0.5 mL acetonitrile, containing internal standard ([2H3, 15N] sorafenib), to 50 μL of plasma sample volume. Separation was achieved on a Waters SymmetryShield RP8 (2.1 mm × 50 mm, 3.5 μm) column at room temperature using an isocratic elution method with acetonitrile/0.1% formic acid in water: 65/35 (v/v) at a flow rate of 0.25 mL/min. Detection was performed using electrospray ionization in positive ion multiple reaction monitoring (MRM) mode by monitoring the ion transitions from m/z 464.9 → 252.0 (sorafenib) and m/z 469.0 → 259.0 (internal standard). Calibration curves were linear in the concentration range of 5-2000 ng/mL. The accuracy and precision values, calculated from three different sets of quality control samples analyzed in quintuplicate on six different days, ranged from 92.86% to 99.88% and from 1.19% to 4.53%, respectively.
AB - A rapid and sensitive liquid chromatography/tandem mass spectrometric (LC/MS/MS) assay was developed for the quantitative determination of sorafenib in human plasma. Sample pretreatment involved simple protein precipitation by the addition of 0.5 mL acetonitrile, containing internal standard ([2H3, 15N] sorafenib), to 50 μL of plasma sample volume. Separation was achieved on a Waters SymmetryShield RP8 (2.1 mm × 50 mm, 3.5 μm) column at room temperature using an isocratic elution method with acetonitrile/0.1% formic acid in water: 65/35 (v/v) at a flow rate of 0.25 mL/min. Detection was performed using electrospray ionization in positive ion multiple reaction monitoring (MRM) mode by monitoring the ion transitions from m/z 464.9 → 252.0 (sorafenib) and m/z 469.0 → 259.0 (internal standard). Calibration curves were linear in the concentration range of 5-2000 ng/mL. The accuracy and precision values, calculated from three different sets of quality control samples analyzed in quintuplicate on six different days, ranged from 92.86% to 99.88% and from 1.19% to 4.53%, respectively.
KW - BAY43-9006
KW - Kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=37749052511&partnerID=8YFLogxK
U2 - 10.1016/j.jpba.2007.10.027
DO - 10.1016/j.jpba.2007.10.027
M3 - Article
C2 - 18309574
AN - SCOPUS:37749052511
SN - 0731-7085
VL - 46
SP - 362
EP - 367
JO - Journal of Pharmaceutical and Biomedical Analysis
JF - Journal of Pharmaceutical and Biomedical Analysis
IS - 2
ER -